EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Comparison of romosozumab versus denosumab treatment on bone mineral density after 1 year in rheumatoid arthritis patients with severe osteoporosis: A randomized clinical pilot study

Takeshi Mochizuki, Koichiro Yano, Katsunori Ikari, Ryo Hiroshima, Ken Okazaki

Modern Rheumatology · 2023

DOI: 10.1093/mr/roac059 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Modern Rheumatology, 2023. Verfasst von Takeshi Mochizuki und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Kamagaya General Hospital, Chiba, Japan. Hauptthemen laut MEDLINE: Osteoporosis, Bone Density Conservation Agents, Arthritis, Rheumatoid, Osteoporosis, Postmenopausal. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To investigate the effect of romosozumab versus denosumab treatment on bone mineral density (BMD), disease activity, and joint damage in patients with rheumatoid arthritis and severe osteoporosis.

Methods

Fifty-one postmenopausal women were enrolled and randomized equally into two groups to receive either romosozumab or the denosumab. Changes (Δ) in the BMD (at lumbar spine, total hip, and femoral neck), disease activity score in 28 joints (DAS28)-erythrocyte sedimentation rate (ESR), and van der Heijde-modified Total Sharp Score (TSS) from baseline to 12 months after treatment were evaluated.

Results

The ΔBMD at 12 months in the romosozumab and denosumab groups were 10.2 ± 5.6% and 5.0 ± 3.1% (p = .002) for the lumbar spine, 3.7 ± 4.9% and 3.5 ± 3.0% (p = .902) for the total hip, and 3.6 ± 4.7% and 3.2 ± 4.9% (p = .817) for the femoral neck, respectively. The ΔDAS28-ESR and ΔTSS at 12 months did not differ between these two groups.

Conclusions

Our results suggest that romosozumab treatment was more effective in increasing the BMD at the lumbar spine than denosumab and may be selected for patients who require a significant increase in the lumbar spine BMD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteoporosisBone Density Conservation AgentsArthritis, RheumatoidOsteoporosis, PostmenopausalHumansFemaleBone DensityDenosumabPilot ProjectsAntibodies, Monoclonal

Stichwörter der Autor:innen

Bone mineral densitydenosumabosteoporosisrheumatoid arthritisromosozumab

Substanzen

DenosumabBone Density Conservation AgentsromosozumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Orthopaedic Surgery, Kamagaya General Hospital, Chiba, Japan.
  • Department of Orthopaedic Surgery, Tokyo Women's Medical University, Tokyo, Japan.
  • Division of Multidisciplinary Management of Rheumatic Diseases, Tokyo Women's Medical University, Tokyo, Japan.

Zitieren

APA

Mochizuki, T., Yano, K., Ikari, K., Hiroshima, R., & Okazaki, K. (2023). Comparison of romosozumab versus denosumab treatment on bone mineral density after 1 year in rheumatoid arthritis patients with severe osteoporosis: A randomized clinical pilot study. Modern Rheumatology. https://doi.org/10.1093/mr/roac059

Vancouver

Mochizuki T, Yano K, Ikari K, Hiroshima R, Okazaki K. Comparison of romosozumab versus denosumab treatment on bone mineral density after 1 year in rheumatoid arthritis patients with severe osteoporosis: A randomized clinical pilot study. Modern Rheumatology. 2023. doi:10.1093/mr/roac059

BibTeX
@article{Mochizuki2023,
  author = {Mochizuki, Takeshi and Yano, Koichiro and Ikari, Katsunori and Hiroshima, Ryo and Okazaki, Ken},
  title = {Comparison of romosozumab versus denosumab treatment on bone mineral density after 1 year in rheumatoid arthritis patients with severe osteoporosis: A randomized clinical pilot study},
  journal = {Modern Rheumatology},
  year = {2023},
  doi = {10.1093/mr/roac059}
}
Kostenlos starten →